June 12 – 17, 2022
The inequitable rollout of COVID-19 vaccines has drawn global attention to the lack of vaccine manufacturing capacity in Africa. The Bill & Melinda Gates Foundation has conducted three analyses to better understand resourcing and market implications of manufacturing at different locations in Africa. This includes (1) a review of market dynamics and selection of three vaccines for deeper analysis; (2) an analysis of the cost-per-dose of vaccines produced at different locations in Africa versus a baseline in South Asia; and (3) an assessment of the market health knock-on effects of potential new entrants. Toggling variables had a range of impacts, and overall, labor source and facility scale were found to be two key differentiators in scenarios. We also found that any idle capacity adds significant cost. For mRNA, where the cost of raw materials was high, the other factors became much less important proportionally.
Please click Download on the upper right corner to see the full abstract.
Casey Selwyn, "Impact of Africa-based manufacturing on cost-per-dose: A theoretical, inside-out analysis" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/116